This Article Full Text Full Text (PDF) All Versions of this Article: 115/3/310    most recent CIRCULATIONAHA.106.665547v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shiroshita-Takeshita, A. Articles by Nattel, S. Search for Related Content PubMed PubMed Citation Articles by Shiroshita-Takeshita, A. Articles by Nattel, S. Related Collections Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2007;115:310-318.)
© 2007 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Model-Dependent Effects of the Gap Junction Conduction–Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs

Akiko Shiroshita-Takeshita, MD; Masao Sakabe, MD; Ketil Haugan, MD; James K. Hennan, PhD; Stanley Nattel, MD

From the Department of Medicine and Research Center (A.S.-T., M.S., S.N.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada; Zealand Pharma A/S (K.H.), Glostrup, Denmark; and Wyeth Research (J.K.H.), Philadelphia, Pa.

Correspondence to Dr Stanley Nattel, Montreal Heart Institute Research Center, 5000 Belanger Street East, Montreal, Quebec H1T 1C8, Canada. E-mail nattel{at}icm.umontreal.ca

Received September 19, 2006; accepted November 10, 2006.

Background— Abnormal intercellular communication caused by connexin dysfunction may be involved in atrial fibrillation (AF). The present study assessed the effect of the gap junctional conduction–enhancing peptide rotigaptide on AF maintenance in substrates that result from congestive heart failure induced by 2-week ventricular tachypacing (240 bpm), atrial tachypacing (ATP; 400 bpm for 3 to 6 weeks), and isolated atrial myocardial ischemia.

Methods and Results— Electrophysiological study and epicardial mapping were performed before and after rotigaptide administration in dogs with ATP and congestive heart failure, as well as in similarly instrumented sham dogs that were not tachypaced. For atrial myocardial ischemia, dogs administered rotigaptide before myocardial ischemia were compared with no-drug myocardial ischemia controls. ATP significantly shortened the atrial effective refractory period (P=0.003) and increased AF duration (P=0.008), with AF lasting >3 hours in all 6-week ATP animals. Rotigaptide increased conduction velocity in ATP dogs slightly but significantly (P=0.04) and did not affect the effective refractory period, AF duration, or atrial vulnerability. In dogs with congestive heart failure, rotigaptide also slightly increased conduction velocity (P=0.046) but failed to prevent AF promotion. Rotigaptide had no statistically significant effects in sham dogs. Myocardial ischemia alone increased AF duration and impaired conduction (based on conduction velocity across the ischemic border and indices of conduction heterogeneity). Rotigaptide prevented myocardial ischemia–induced conduction slowing and AF duration increases.

Conclusions— Rotigaptide improves conduction in various AF models but suppresses AF only for the acute ischemia substrate. These results define the atrial antiarrhythmic profile of a mechanistically novel antiarrhythmic drug and suggest that gap junction dysfunction may be more important in ischemic AF than in ATP remodeling or congestive heart failure substrates.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				I. Savelieva and J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace, June 1, 2008; 10(6): 647 - 665. [Abstract] [Full Text] [PDF]

				X. Lin, C. Zemlin, J. K. Hennan, J. S. Petersen, and R. D. Veenstra Enhancement of ventricular gap-junction coupling by rotigaptide Cardiovasc Res, May 12, 2008; (2008) cvn100v2. [Abstract] [Full Text] [PDF]

				M. Sakabe, A. Shiroshita-Takeshita, A. Maguy, B. J.J.M. Brundel, A. Fujiki, H. Inoue, and S. Nattel Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia Cardiovasc Res, April 1, 2008; 78(1): 63 - 70. [Abstract] [Full Text] [PDF]

				M. Sakabe, A. Shiroshita-Takeshita, A. Maguy, C. Dumesnil, A. Nigam, T.-K. Leung, and S. Nattel Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling Circulation, November 6, 2007; 116(19): 2101 - 2109. [Abstract] [Full Text] [PDF]

				P. G. Platonov Interatrial conduction in the mechanisms of atrial fibrillation: from anatomy to cardiac signals and new treatment modalities Europace, November 1, 2007; 9(suppl_6): vi10 - vi16. [Abstract] [Full Text] [PDF]

				S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]